A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan

Table 2 Final parameter estimates describing the piperaquine population pharmacokinetics in women with uncomplicated P . falciparum malaria

	Population estimates [RSE %]	95% CI	BSV/BOV† [RSE %]	95% CI
CL/F (L/h)	44.6 [9.90]	37.3-53.8	22.5 [31.5]	14.6-29.0
V_C/F (L)	1820 [11.5]	1450-2240	-	-
Q₁/F (L/h)	47.7 [19.0]	32.4-69.2	-	-
V_P1/F (L)	15900 [12.3]	12600-20400	-	-
Q₂/F (L/h)	352 [11.1]	283-431	-	-
V_P2/F (L)	7520 [17.1]	5520-10500	-	-
MTT (h)	1.70 [8.05]	1.45-2.00	60.7 [22.8] †	44.5-76.7
RUV	0.0973 [5.90]	0.0753-0.120	-	-
No. of trans comp	3 fix	-	-	-
F (%)	100 fix	-	34.7 [59.2]	9.52-54.9
			64.8 [15.2] †	52.8-76.0

Coefficient of variation (%CV) for between-subject variability (BSV) and (†) between occasion variability (BOV) were calculated as the [exp(estimated variance)-1]^1/2. Relative standard errors (RSE) and the 95% confidence intervals (CI) were based on 868 successful stratified bootstrap runs (out of 1000) and presented as 100×(standard deviation/mean value) and as 2.5 to 97.5 percentiles, respectively.
CL/F is the apparent elimination clearance. Vc/F is the apparent volume of distribution of the central compartment. Q1/F and Q2/F is the inter-compartment clearance between the central and first and second peripheral compartment, respectively. VP1/F and VP2/F is the apparent volume of distribution of first and second peripheral compartment, respectively. MTT is the mean transit time of the absorption model. RUV is the variance of the residual variability. No. of trans comp is the number of transit compartments used in the absorption phase. F represents the relative bioavailability.

ISSN: 1475-2875